“We have added 4 new buildings which add to our solid-phase and liquid-phase peptide facilities at our Shanghai production site positioning AmbioPharm as the go-to source for all peptide API needs that our partners have. This is in addition to the manufacturing expansion which was completed at our USA headquarters in mid-2020,” stated Chris Bai, CEO and co-founder of AmbioPharm.

The company has also established a new office in Zurich, Switzerland, which is headed by Kathleen Noack, Vice President of European Sales and Marketing. Additionally, Michael Postlethwaite has joined the AmbioPharm Europe team from Swiss competitor Bachem as Sales Director,.

“We are delighted to add two highly experienced seasoned professionals to our European team. Both Ms. Noack and Dr. Postlethwaite come with a wealth of peptide API development knowledge to establish and extend our European partnerships,” said Jim Hampton, AmbioPharm's Executive Vice President of GMP Sales and co-founder.